Advertisement

Topics

Grünenthal Company Profile

17:47 EDT 29th August 2016 | BioPortfolio

Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti Grünenthal sono commercializzati in oltre 80 Paesi e il numero delle filiali è in continua crescita. Grünenthal occupa circa 4.800 persone a livello mondiale, persone che hanno dato un grande contributo per il successo della Società.L'ulteriore consolidamento attraverso una ricerca innovativa è una parte integrante della politica della nostra Società. L'ambizione di Grünenthal è quella di essere una società leader nella Ricerca e Sviluppo in campi selezionati: l'area dolore è la nostra competenza core.

Location

Via Correggio, 43
Milano
20149
Italy

Contact

Phone: 39-02-43051
Fax: 39-02-430555
Email: dg@grunenthal.com


News Articles [26 Associated News Articles listed on BioPortfolio]

Germany’s Grünenthal to acquire Almirall’s Mexican operations

Grünenthal Group has entered into a definitive agreement with Almirall under which Grünenthal will…

Grünenthal to capitalize on Axxam’s drug discovery platform

Family-owned German drugmaker Grünenthal has entered into a collaboration with Italian biotech company…

Helsinn links with Grünenthal for Akynzeo marketing in Chile

Privately-held Swiss drugmaker Helsinn and Grünenthal Group have signed an exclusive agreement for the…

Grünenthal gets rights to AstraZeneca’s Zurampic for Europe and Latin America

Anglo-Swedish pharma major AstraZeneca has entered into a licensing agreement with Grünenthal for the…

Grünenthal Group to acquire Almirall’s Mexico unit for about €50 million

Privately-held Grünenthal Group said it has signed a definitive agreement to buy Almirall Group’s Mexico-based business for about €50 million ,to enter into the gastroenterology segment and ...

Grünenthal Gains Europe, Latin America Rights to AstraZeneca's Zurampic

AstraZeneca said today it has granted exclusive rights to the gout-associated hyperuricemia drug Zurampic® (lesinurad) in Europe and Latin America to Grünenthal, in a licensing deal that co...

Grünenthal Group to acquire Almirall’s Mexico unit for about 50 million euro

Privately-held Grünenthal Group said it has signed a definitive agreement to buy Almirall Group’s Mexico-based business for about 50 million euros to enter into the gastroenterology segment and exp...

AstraZeneca licenses gout drug Zurampic to Grünenthal in Europe and Latin America

UK drugmaker AstraZeneca (LSE: AZN) on Thursday said it has entered into a licensing agreement worth up to $230 million giving Grünenthal GmbH rights to the gout drug Zurampic (lesinurad) in Eur...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Grünenthal

Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti...

Gr?nenthal

Grünenthal GmbH

Nil

More Information about "Grünenthal" on BioPortfolio

We have published hundreds of Grünenthal news stories on BioPortfolio along with dozens of Grünenthal Clinical Trials and PubMed Articles about Grünenthal for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Grünenthal Companies in our database. You can also find out about relevant Grünenthal Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record